|View printer-friendly version|
|October 03, 2016 9:57 a.m.|
|Teva Completes Acquisition of Anda, Inc.|
Acquisition Reinforces Teva's Strategy and Enhances Teva’s Offerings to More Patients throughout the U.S.
“We are pleased that
“We are excited to become part of Teva’s distribution network to support
our customers and patients across the country,” said Charles D.
Teva currently has over 300 product registrations pending
Teva's Safe Harbor Statement under the
This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our specialty products, especially Copaxone® (which
faces competition from orally-administered alternatives and a generic
version); our ability to integrate
Teva Pharmaceutical Industries Ltd.